High-potential biotech companies INOVOTION and LXRepair specialized in DNA repair assays have partnered with CHU Grenoble Alpes and the Institut for Avanced Biosciences (IAB) in a 900k€ R&D contract awarded by the Région Auvergne-Rhône-Alpes.
The project coordinated by INOVOTION’s R&D department will develop a disruptive new method for screening and validating new drugs, to widen and accelerate the development of new therapies for cancer and other diseases. The new method will also allow precision-medicine screening of patients, to select treatments based on their response to specific drugs.
Leave a Reply
Want to join the discussion?Feel free to contribute!